IN2012DN04944A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN04944A IN2012DN04944A IN4944DEN2012A IN2012DN04944A IN 2012DN04944 A IN2012DN04944 A IN 2012DN04944A IN 4944DEN2012 A IN4944DEN2012 A IN 4944DEN2012A IN 2012DN04944 A IN2012DN04944 A IN 2012DN04944A
- Authority
- IN
- India
- Prior art keywords
- expression level
- polq
- breast cancer
- patient
- gene
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 abstract 5
- 208000026310 Breast neoplasm Diseases 0.000 abstract 5
- 102100029766 DNA polymerase theta Human genes 0.000 abstract 3
- 101001094659 Homo sapiens DNA polymerase kappa Proteins 0.000 abstract 3
- 101000865085 Homo sapiens DNA polymerase theta Proteins 0.000 abstract 3
- 101150098894 Polq gene Proteins 0.000 abstract 2
- 230000002068 genetic effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000002493 microarray Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09306096A EP2322658A1 (en) | 2009-11-13 | 2009-11-13 | Signature for the diagnosis of breast cancer aggressiveness and genetic instability |
| PCT/EP2010/067401 WO2011058143A1 (en) | 2009-11-13 | 2010-11-12 | Signature for the diagnosis of breast cancer aggressiveness and genetic instability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN04944A true IN2012DN04944A (enrdf_load_stackoverflow) | 2015-09-25 |
Family
ID=41647234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN4944DEN2012 IN2012DN04944A (enrdf_load_stackoverflow) | 2009-11-13 | 2010-11-12 |
Country Status (11)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103827314A (zh) * | 2011-05-18 | 2014-05-28 | 国家科学研究中心 | 用于诊断癌侵袭性和遗传不稳定性的标记 |
| CN104145030B (zh) * | 2012-01-05 | 2016-10-12 | 国家科学研究中心 | 用于诊断肺癌侵袭性和遗传不稳定性的标记 |
| CN102994627B (zh) * | 2012-06-21 | 2015-04-15 | 宁波海尔施基因科技有限公司 | 一种肿瘤用药个体化指导的检测方法 |
| US9157124B2 (en) | 2012-09-18 | 2015-10-13 | Institute For Cancer Research | Systems and methods for diagnosing a predisposition to develop colon cancer |
| FR3019821A1 (fr) * | 2014-04-14 | 2015-10-16 | Centre Nat Rech Scient | Nouveaux anticorps utiles pour le diagnostic et le pronostic du cancer |
| US10724100B2 (en) | 2015-09-16 | 2020-07-28 | Institute For Cancer Research | Systems and methods for treating patients having a genetic predisposition to develop prostate cancer |
| US10760081B2 (en) | 2015-10-07 | 2020-09-01 | New York University | Compositions and methods for enhancing CRISPR activity by POLQ inhibition |
| AU2016340878A1 (en) * | 2015-10-19 | 2018-05-10 | Dana-Farber Cancer Institute, Inc. | Polymerase Q as a target in HR-deficient cancers |
| CN106011262A (zh) * | 2016-06-29 | 2016-10-12 | 北京泱深生物信息技术有限公司 | 子宫内膜癌诊治标志物及其应用 |
| WO2020014297A1 (en) * | 2018-07-11 | 2020-01-16 | The Johns Hopkins University | Identification of dna polymerase theta inactivation mechanism |
| WO2020142551A1 (en) * | 2018-12-31 | 2020-07-09 | Tempus Labs | A method and process for predicting and analyzing patient cohort response, progression, and survival |
| US11875903B2 (en) | 2018-12-31 | 2024-01-16 | Tempus Labs, Inc. | Method and process for predicting and analyzing patient cohort response, progression, and survival |
| CN112646864A (zh) * | 2020-12-30 | 2021-04-13 | 杭州联川基因诊断技术有限公司 | 一种检测esr1基因表达的引物、探针、试剂盒和检测方法 |
| CN112725444A (zh) * | 2020-12-30 | 2021-04-30 | 杭州联川基因诊断技术有限公司 | 一种检测pgr基因表达的引物、探针、试剂盒和检测方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101146806B1 (ko) | 2003-03-12 | 2012-05-22 | 메이브릿지 리미티드 | 프탈라지논 유도체 |
| EP2305221B1 (en) | 2003-12-01 | 2015-05-20 | Kudos Pharmaceuticals Limited | DNA damage repair inhibitors for treatment of cancer |
| WO2007001684A2 (en) | 2005-05-19 | 2007-01-04 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Inhibiting dna polymerase beta to enhance efficacy of anticancer agents |
| AT504702A1 (de) * | 2006-12-22 | 2008-07-15 | Arc Austrian Res Centers Gmbh | Set von tumormarkern |
| KR20090101362A (ko) | 2006-12-26 | 2009-09-25 | 파마시클릭스, 인코포레이티드 | 병용 치료에 있어서 히스톤 디아세틸라제 억제제 이용 및 생체표지 감시 방법 |
| NZ585012A (en) | 2007-10-03 | 2012-06-29 | Eisai Inc | Parp inhibitor compounds, compositions and methods of use |
-
2009
- 2009-11-13 EP EP09306096A patent/EP2322658A1/en not_active Withdrawn
-
2010
- 2010-11-12 EP EP10776712.1A patent/EP2499258B1/en not_active Not-in-force
- 2010-11-12 AU AU2010317877A patent/AU2010317877A1/en not_active Abandoned
- 2010-11-12 PT PT107767121T patent/PT2499258E/pt unknown
- 2010-11-12 WO PCT/EP2010/067401 patent/WO2011058143A1/en active Application Filing
- 2010-11-12 IN IN4944DEN2012 patent/IN2012DN04944A/en unknown
- 2010-11-12 ES ES10776712.1T patent/ES2522992T3/es active Active
- 2010-11-12 CA CA2780479A patent/CA2780479A1/en not_active Abandoned
- 2010-11-12 BR BR112012011247A patent/BR112012011247A2/pt not_active IP Right Cessation
- 2010-11-12 CN CN2010800565327A patent/CN102791879A/zh active Pending
-
2011
- 2011-05-18 US US13/110,749 patent/US8865408B2/en not_active Expired - Fee Related
-
2012
- 2012-05-09 IL IL219697A patent/IL219697A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2322658A1 (en) | 2011-05-18 |
| BR112012011247A2 (pt) | 2016-11-22 |
| CA2780479A1 (en) | 2011-05-19 |
| AU2010317877A1 (en) | 2012-06-07 |
| US20120021935A1 (en) | 2012-01-26 |
| EP2499258A1 (en) | 2012-09-19 |
| CN102791879A (zh) | 2012-11-21 |
| EP2499258B1 (en) | 2014-08-06 |
| PT2499258E (pt) | 2014-11-04 |
| ES2522992T3 (es) | 2014-11-20 |
| WO2011058143A1 (en) | 2011-05-19 |
| IL219697A0 (en) | 2012-07-31 |
| US8865408B2 (en) | 2014-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN04944A (enrdf_load_stackoverflow) | ||
| Chi et al. | Downregulation of hsa_circ_0000285 serves as a prognostic biomarker for bladder cancer and is involved in cisplatin resistance. | |
| UA110790C2 (uk) | Спосіб передбачування рецидиву раку молочної залози при ендокринному лікуванні | |
| WO2013182912A3 (en) | Method for the diagnosis, prognosis and treatment of lung cancer metastasis | |
| AR061136A1 (es) | Procedimiento | |
| MX365421B (es) | Método in-vitro para diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata usando c-maf. | |
| MX2020001156A (es) | Metodo para el pronostico y tratamiento de metastasis de cancer. | |
| ES2721639T3 (es) | Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama | |
| MX366164B (es) | Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata. | |
| NZ705645A (en) | Method to use gene expression to determine likelihood of clinical outcome of renal cancer | |
| MX2019000091A (es) | Metodo para el pronostico y tratamiento de cancer metastasico de los huesos originado de cancer de mama. | |
| EP4083233A3 (en) | Method for using gene expression to determine prognosis of prostate cancer | |
| WO2012174256A3 (en) | Dna methylation profiles in cancer | |
| MX2009010439A (es) | Variantes geneticas de chr2 y chr16 como marcadores para el uso en valoracion, diagnosis, prognosis y tratamiento de riesgo de cancer de mama. | |
| MX357402B (es) | Metodo para predecir el pronostico de cancer de mama. | |
| WO2008037700A3 (en) | Methods for breast cancer prognosis | |
| IN2012DN01979A (enrdf_load_stackoverflow) | ||
| ATE481504T1 (de) | Für die vorhersage des ansprechens maligner neoplasie auf eine auf taxan beruhende medizinische behandlung geeignete genetische veränderung | |
| MX2011007795A (es) | Polinucleotido que comprende secuencias de gliadinas de trigo y su uso para silenciamiento mediante rnai. | |
| WO2014184679A3 (en) | Method for the prognosis and treatment of renal cell carcinoma metastasis | |
| EA201290107A1 (ru) | Способ определения пациента как восприимчивого или не восприимчивого к иммунотерапии | |
| WO2011021177A3 (en) | Compositions and methods for prognosis and treatment of prostate cancer | |
| WO2011134670A3 (en) | Diagnostic method for predicting the response of a patient to chemovirotherapy or radiovirotherapy | |
| MX2013004747A (es) | Marcadores de gen de sangre periferica para el diagnostico temprano de la enfermedad de parkinson. | |
| WO2012166700A3 (en) | Molecular profiling of a lethal tumor microenvironment |